Gepirone Extended-Release: First Approval

Gepirone HCL extended-release (gepirone ER; EXXUA (TM)), an oral, selective serotonin (5HT)1A receptor agonist formulated for once-daily administration, has been developed by Fabre-Kramer Pharmaceuticals, Inc. for the treatment of psychiatric disorders, including major depressive disorder (MDD). In September 2023, gepirone ER was approved in the USA for the treatment of adults with MDD. This article summarizes the milestones in the development of gepirone ER leading to this first approval for the treatment of adults with MDD.

Automated summary

This article summarizes the milestones in the development of Gepirone ER, leading to its first approval for the treatment of major depressive disorder in adults.